Latest Putamen Stories
-- Longer term follow-up indicates modest efficacy in primary and related endpoints -- SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease.
A growth factor used in clinical experiments to rescue dying brain cells in Parkinson patients may cause unwanted weight loss if delivered to specific areas of the brain, according to University of Florida researchers in the March online edition of Molecular Therapy.
Analysis of the brain of a patient suffering from Parkinson's Disease has shown that the experimental treatment he received caused regrowth of the nerve fibres that are lost in this disease. This is the first time that any treatment has been shown to reverse the loss of nerve fibres in Parkinson's Disease.
- Emitting flashes of light; glittering.